The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030: By Roots Analysis:

narender.shukla@rootsanalysis.co

289
views

Recent advances in informationtechnology and biomedical science have enabled the development of a number ofversatile digital solutions that are capable of either mimicking or augmenting,the fundamental qualities of pharmacological interventions

Roots Analysis has announced the addition of “Digital Health Market:Focus on Digital Therapeutics (2nd Edition),2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution andCombination Solution), Type of Therapy (Curative and Preventive), and Purposeof Solution (Medication Replacement and Medication Augmentation” report to itslist of offerings.

According to experts, digital therapeuticsolutions are primarily based on behavior modification and are designed toaddress a variety of therapeutic needs across a wide range of diseaseindications. On the other hand, several digital solutions have been developedto enable remote doctor-patient consultations. Such solutions witnessed a surgein adoptions amidst the COVID-19 pandemic.

To order this 500+ page report, which features160+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/digital-health-market/208.html

Key Market Insights

Nearly 230 digital therapeutic solutions arecurrently available / under development

Close to 45% of the aforementioned solutionsare standalone software applications targeting more than 60 unique indications.

Over 85% of digital therapeutic solutions areintended to replace medication

Such solutions are currently available / beingdeveloped to treat neurological disorders (27%), mental health problems (24%),and certain metabolic disorders (24%). Alternatively, some digital healthproducts are designed to augment the effect of conventional therapeutics andare currently being considered for treating substance use disorders and fewmental health problems.

220+ clinical trials, focused on digitaltherapeutics, have been registered since 2004

Around 80,000patients have been enrolled in clinical research initiatives aimed to validatethe efficacy of digital therapeutics, and generate real world evidenceconcerning their efficacy and safety. Close to 50% of such trials have been /are being conducted in the US.

Nearly USD 1.9 billion invested by both privateand public investors in this domain

~85% of the total capital raised for digitaltherapeutics-related initiatives was from venture capital investors, featuringover 370 participants.

Partnership activity in this field has grown ata CAGR of ~42%, between 2015 and 2019

More than 70% of the reported deals wereestablished after 2017, with the maximum activity being reported in 2019.Majority of the instances captured in the report were focused on pilot productoffering (29%) and research and development agreements (21%).

North America and Europe are anticipated tocapture over 70% of the market share by 2030

The market inAsia-Pacific regions is anticipated to grow at a relatively faster pace(23.2%). In 2030, digital solutions targeting metabolic disorders are likely torepresent the largest market share, in terms of revenues from product sales(26%), followed by those intended for mental health problems (20%) andneurological disorders (19%).

To request a sample copy / brochure of thisreport, please visit this - https://www.rootsanalysis.com/reports/208/request-sample.html

Key Questions Answered

§ Who are the leading players engaged in the development ofdigital therapeutic solutions?

§ What are the most popular therapeutic areas addressed bydigital health solutions?

§ What are the key factors influencing the price of digitaltherapeutics?

§ What is the trend of capital investments in the digitaltherapeutics market?

§ Which partnership models are commonly adopted bystakeholders in this industry?

§ What type of marketing strategies are being adopted bydevelopers in this domain?

§ How is the COVID-19 pandemic likely to impact the digitaltherapeutics market?

§ How is the current and future opportunity likely to bedistributed across key market segments?

§ What are the anticipated future trends related to digitaltherapeutics?

The USD 8.86 billion (by 2030) financialopportunity within the digital therapeutics market has been analyzed across thefollowing segments:

§ Typeof Solution

§ Standalone SoftwareApplication

§ Software Application+ Device + Personal Coach

§ Software Application+ Device + AI Support

§ Software Application+ Device

§ Software Application+ AI Support

§ Software Application+ Personal Coach

§ Other Types ofSolutions

§ Purposeof Solution

§ MedicationReplacement

§ MedicationAugmentation

§ Typeof Therapy

§ Curative

§ Preventive

§ BusinessModel

§ Businessto Consumer (Patients and Caregivers)

§ Businessto Business (Healthcare Providers, Payers, Employers andPharmaceutical Companies)

§ TherapeuticAreas

§ CardiovascularDisorders

§ ChronicPain

§ MentalHealth Problems

§ MetabolicDisorders

§ NeurologicalDisorders

§ RespiratoryDisorders

§ SleepDisorders

§ SubstanceUse Disorders

§ Others

§ KeyGeographical Regions

§ NorthAmerica

§ Europe

§ Asia-Pacific

§ Restof the world

The report features inputs from eminentindustry stakeholders, according to whom, digital therapeutic solutions arelikely to witness enhanced adoption due to their broader applicability, remoteguidance and other advanced features, thereby, offering lucrative opportunitiesto their developers. The report includes detailed transcripts of thediscussions held with following industry experts:

§ Eran Ofir (Co-Founderand ChiefExecutive Officer, Somatix)

§ Edouard Gasser(Co-Founder and Chief Executive Officer, Tilak Healthcare)

§ Stephanie Tilenius(Co-Founderand Chief Executive Officer, Vida Health)

§ Adam Kaufman (Chief ExecutiveOfficer, CanaryHealth)

§ Vijay Ravindran (Chief ExecutiveOfficer, Floreo)

§ Palakh R Sarogi (VicePresident, Marketing, Wellthy Therapeutics),Arani Sarkra (Senior Manager, Consumer Marketing, Wellthy Therapeutics)and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics)

§ Amelie Janson(Communication Manager, Voluntis)

§ Anonymous (Founderand Chief Executive Officer, UK based Small-sized Company)

Theresearch covers brief profiles of key players engaged in the development ofdigital therapeutic solutions; other popular industry players featured in thereport include:

§ Akili Interactive

§ Beats Medical

§ Big Health

§ Bold Health

§ Click Therapeutics

§ CureApp

§ dreem

§ Ehave

§ Ginger

§ Happify Health

§ inMotion VR

§ Kaia Health